BioSpace News Archive

Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director.

Dicerna™ Pharmaceuticals, Inc.(Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 8:45 am EST in New York City.

A federal court has ordered two Tennessee-based companies and their owner to stop distributing drugs, dietary supplements and devices until the companies comply with the Federal Food, Drug, and Cosmetic (FD&C) Act and other requirements listed in a consent decree.

Addus HomeCare Corporation (Nasdaq: ADUS) (“Addus” or the “Company”), a provider of comprehensive home care services, today announced that it has commenced a proposed public offering of 2,000,000 shares of its common stock.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of Robert Weiskopf as Chief Financial Officer (CFO).

HCA Healthcare today announced its first national “Crush the Crisis” opioid take back day

Sixteen organizations representing health, environmental, farmer, and farmworker communities joined together to call on EPA to remove glyphosate from the marketplace.

America’s Physician Groups announced the results of its 2019 Standards of Excellence™ member survey.

Willow Biosciences Inc. is pleased to announce it has engaged The Howard Group as its capital markets communications advisor to assist with both traditional and online initiatives targeting institutional and retail investing groups as well as the larger investment community.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced an agreement with Verseau Therapeutics for the delivery of systems pharmacology pharmacokinetic and target engagement analysis to provide early feasibility assessments for the treatment of cancer.